Publications by authors named "Christopher D Hart"

Claim this Profile
R
Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.
Benedict J Panizza, Stephen John O'Leary, Christopher David Hart, Chandra Sai Diwakarla, Catherine Barnett

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary Approach.
Jasper de Boer, Rebecca Barnett, Anthony Cardin, Michelle Cimoli, Lauren Davies, Christopher D Hart

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality indicators in breast cancer care: An update from the EUSOMA working group.
Laura Biganzoli, Lorenza Marotti, Christopher D Hart, Luigi Cataliotti, Bruno Cutuli

Eur J Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
Christopher D Hart, Alessia Vignoli, Leonardo Tenori, Gemma Leonora Uy, Ta Van To

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Luca Malorni, Silvano Piazza, Yari Ciani, Cristina Guarducci, Martina Bonechi, Christopher D Hart

Oncotarget· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolomics in Breast Cancer: Current Status and Perspectives.
Christopher D Hart, Leonardo Tenori, Claudio Luchinat, Angelo Di Leo

Adv Exp Med Biol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes.
Christopher D Hart, Angelo Di Leo

Breast· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using CTCs for pharmacogenomic analysis.
Christopher D Hart, Francesca Galardi, Marta Pestrin, Francesca De Luca, Emanuela Risi

Pharmacol Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes.
Christopher D Hart, Giuseppina Sanna, Olimpia Siclari, Laura Biganzoli, Angelo Di Leo

Breast· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Christopher D Hart, Ilenia Migliaccio, Luca Malorni, Cristina Guarducci, Laura Biganzoli

Nat Rev Clin Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.
Ilenia Migliaccio, Luca Malorni, Christopher D Hart, Cristina Guarducci, Angelo Di Leo

BMC Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.
Christopher D Hart, Richard H De Boer

Onco Targets Ther· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis